1661P Antitumor efficacy and immune profiling of the mouse ortholog of nemvaleukin alfa, a novel engineered IL-2 fusion protein, in an orthotopic mouse model of small cell lung cancer alone or in combination with standard chemotherapy

Abstract

Small cell lung cancer (SCLC) is a deadly cancer with a 5-year survival of less than 7%. Immune checkpoint blockade was recently approved but survival benefits are limited. nemvaleukin alfa (‘nemvaleukin’; formerly ALKS 4230), a novel engineered IL-2 fusion protein currently under phase I/II study, is designed to selectively expand tumor-killing CD8+ and NK cells. Here, utilizing a novel SCLC murine model, we investigated the effects of RDB 1462, the murine ortholog of nemvaleukin, on tumor growth and immune cell profiles.